Please find attached Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.3 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Titan Biotech's board approved unaudited results for Q2 and H1 FY26 on November 11, 2025. Standalone revenue from operations grew to ₹5,435.47 lakhs in Q2 FY26 from ₹3,989.11 lakhs in Q2 FY25, a jump of about 36%. For the half-year, standalone revenue rose to ₹10,085.11 lakhs from ₹8,300.57 lakhs. Standalone profit after tax came in at ₹686.25 lakhs for Q2 (vs ₹500.35 lakhs YoY) and ₹1,302.33 lakhs for H1 (vs ₹1,070.31 lakhs YoY). EPS stood at ₹8.30 for the quarter and ₹15.76 for the half-year on a standalone basis. Consolidated PAT for Q2 was ₹776.47 lakhs (including ₹90.22 lakhs share from associates Peptech Biosciences and Titan Media). The auditor issued an unqualified limited review report on both sets of results. The company noted that freight has been reclassified — added to both revenue and other expenses to neutralise its effect — so the headline revenue growth partly reflects this accounting change.
Strong YoY growth in both revenue and profit signals improving business momentum, which is generally positive for shareholders. The clean auditor report with no qualifications removes a key risk overhang. Note that part of the revenue jump is due to freight reclassification, so underlying like-for-like growth is somewhat lower but still healthy.